Latest Information Update: 17 Jan 2007
At a glance
- Originator SuperGen
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological disorders
Most Recent Events
- 17 Jan 2007 Discontinued - Phase-I/II for Haematological disorders (Chemotherapy-induced, Radiation-induced, Prevention) in USA (unspecified route)
- 17 Jan 2007 Discontinued - Phase-I/II for Chemoprotection and Radioprotection in USA (unspecified route)
- 08 Jan 2001 No-Development-Reported for Chemoprotection and Radioprotection in USA (Unknown route)